Detalhe da pesquisa
1.
Catastrophic chemotherapy toxicity leading to diagnosis of Fanconi anaemia due to FANCD1/BRCA2 during adulthood: description of an emerging phenotype.
J Med Genet
; 59(9): 912-915, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34697207
2.
An Australian mainstream genetic testing program: Clinicians views about current and future practices.
Asia Pac J Clin Oncol
; 20(1): 119-127, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37985938
3.
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer.
Prostate Cancer Prostatic Dis
; 27(1): 136-143, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37147359
4.
Targeting lipid metabolism in metastatic prostate cancer.
Ther Adv Med Oncol
; 15: 17588359231152839, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36743527
5.
Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer.
Asia Pac J Clin Oncol
; 18(5): e414-e419, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35098668
6.
Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin.
Cancers (Basel)
; 14(19)2022 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36230715
7.
Mainstream consent programs for genetic counseling in cancer patients: A systematic review.
Asia Pac J Clin Oncol
; 17(3): 163-177, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32309911
8.
PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma.
Cancer Rep (Hoboken)
; 4(2): e1327, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33314769
9.
Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer.
JCO Oncol Pract
; 17(2): e204-e216, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32970524
10.
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.
EBioMedicine
; 72: 103625, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34656931
11.
Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer).
BMJ Open
; 10(1): e033667, 2020 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31988233